Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of subcutaneous extended-release olanzapine in adults with schizophrenia
2022-001865-11Phase 3Completed
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olanzapine in schizophrenia (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Change from baseline to week 8 in PANSS total score. Started Jan 2023; status: completed.
02
Drugs
olanzapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2022-001865-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001865-11.